Prescribing information

 

Cosentyx is indicated alone or in combination with methotrexate, for the treatment of active PsA in adult patients when the response to previous DMARDs has been inadequate;  for the treatment of active AS in adults who have responded inadequately to conventional therapy;  and for the treatment of active nr-axSpA, with objective signs of inflammation, as indicated by elevated C-reactive protein and/or MRI evidence, in adults who have responded inadequately to NSAIDs.

Fast and lasting efficacy2–4

Did you know?

Registry data show that the majority of biologic-initated PsA patients present with 3+ manifestations (n=354)6

  Cosentyx has demonstrated fast and lasting efficacy in all 6 key PsA manifestations*1,3–5,7,8

  Cosentyx is recommended by EULAR* and NICE for use in PsA as a first-line biologic after DMARD failure9,10

 

Dive into the data below to see how Cosentyx can help your PsA patients LOOK, MOVE and FEEL better

Don't miss EXCEED

The first head-to-head trial with a specific rheumatology primary endpoint to evaluate the efficacy and safety of Cosentyx vs adalimumab in patients with active PsA.11

Box with the text: Click here to download our summary of the EXCEED trial

 

Take the next step

We’re here to support you with dedicated representatives up and down the country. Let us connect you with your local representative to discuss how you can get the most out of Cosentyx.

Or find out more using the links below…

Arrow with the text: Hear from the experts. Click image to find out more

Arrow with the text: Get to know the Cosentyx safety profile. Click image to find out more

Arrow with the text: Why Cosentyx in axSpA? Click image to find out more

Arrow with the text: Can targeting IL-17A make the difference? Click image to find out more

*Recommendation 6: In patients with peripheral arthritis and an inadequate response to at least one csDMARD, therapy with a bDMARD should be commenced; when there is relevant skin involvement, an IL-17 inhibitor or IL-12/23 inhibitor may be preferred.9
Cosentyx 150 mg group includes placebo-switchers and patients who escalated to 300 mg starting at week 128 or later, after a protocol amendment.8
The primary endpoint of the FUTURE 2 study was ACR20 response at Week 24 and was met (Cosentyx 300 mg: 54%, Cosentyx 150 mg: 51%, placebo: 15%; P<0.0001 for both).1§As observed in patients (94 with Cosentyx 150 mg) with this symptom at baseline.1
As observed in patients (40 with Cosentyx 150 mg) with this symptom at baseline.1
¥The primary endpoint of the TRANSFIGURE study was percentage change in total fingernail NAPSI score from baseline to week 16 and was met (Cosentyx 300 mg: -45.3%, placebo: -10.8%; P<0.001).3
The primary endpoint of the MAXIMISE study was met. ASAS20 response at Week 12: Cosentyx 300 mg 63%, placebo 31%; P<0.001 (multiple imputation).5

ACR, American College of Rheumatology; AS, ankylosing spondylitis; ASAS, Assessment in SpondyloArthritis international Society; axSpA, axial spondyloarthritis; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; IL, interleukin; NAPSI, Nail Psoriasis Severity Index; NSAID, non-steroidal anti-inflammatory drug; nr-axSpA, non-radiographic axial spondyloarthritis; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, plaque psoriasis; s.c., subcutaneous.

  1. McInnes IB et al. Lancet. 2015;386:1137–46.
  2. Deodhar A et al. Arthritis Rheumatol. 2020 (epub ahead of print).
  3. Reich K et al. Br J Dermatol. 2019;181:954–66.
  4. Thaci D et al. J Am Acad Dermatol. 2015;73:400–9.
  5. Baraliakos X et al. Ann Rheum Dis. 2019;78. Abstract OP0235.
  6. Ogdie A et al. Arthritis Rheumatol. 2019; 71 (suppl. 10). Abstract 2475.
  7. Leung YY et al. Front Med (Lausanne). 2018;5:246.
  8. McInnes IB et al. Lancet Rheumatol. 2020;2:227–35.
  9. Gossec L et al. Ann Rheum Dis. 2020;79: 700–12.
  10. NICE guideline TA445. Available at: https://www.nice.org.uk/guidance/ta445/chapter/1-Recommendations (Accessed January 2021).
  11. McInnes IB et al. Lancet. 2020;395:1496–1505.
  12. Lee S et al. Pharmacy and Therapeutics. 2010;35:680–9.
  13. Reich K et al. Br J Dermatol. 2020 (ePub ahead of print).
  14. Feld J et al. Nat Rev Rheumatol. 2018;14:363–71.
  15. Gottlieb AB et al. J Dermatol Treat. 2006;17:343–52.
  16. Ritchlin CT et al. N Engl J Med. 2017;376:957–70.
Rate this content: 
No votes yet
UK | February 2021 | 101127
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]